CHMP recommends Prezista in treatment-naïve HIV
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended a label extension for Janssen-Cilag'sHIV protease inhibitor Prezista (darunavir) to include its use as part of an anti-HIV combination regimen, co-administered with low-dose ritonavir, in treatment-naïve HIV-1 infected adults. This indication comes with a new strength of 400mg film-coated tablet.